文献速递胸部肿瘤

初治晚期非小细胞肺癌患者循环固有免疫标志物与结局

Circulating innate immune markers and outcomes in treatment-naïve advanced non-small cell lung cancer patients.
PubMed 文献 · Eur J Cancer · 2019-01-14

研究前瞻性纳入2012年12月至2015年7月148例适合一线铂类化疗的初治晚期非小细胞肺癌患者,检测NK细胞表型、NCR基因型及配体、血细胞计数和LDH。单因素分析中单核细胞增多、中性粒细胞增多、白细胞增多、高LDH、高sBAG6及NCR3转录本降低与总生存差相关;多因素分析中NCR3转录本水平是唯一与总生存(P=0.003)和无进展生存(P=0.009)独立相关的固有免疫参数。

要点

  • 单核细胞增多、中性粒细胞增多、白细胞增多、高LDH、高sBAG6及NCR3转录本降低与总生存差相关。
  • NCR3转录本水平与年龄、转移部位数、单核细胞计数、LDH及sBAG6水平相关。
  • 多因素分析中NCR3转录本水平是唯一与总生存和无进展生存独立相关的固有免疫参数。

核心结论

  • 这些生物标志物相互关联,与炎症过程相关的参数与NCR3转录本水平降低有关。
  • NCR3转录本水平与初治晚期非小细胞肺癌患者结局独立相关。

研究设计与样本

  • 前瞻性研究,纳入2012年12月至2015年7月适合一线铂类化疗的初治晚期非小细胞肺癌患者148例。
  • 第一周期前采集血样用于新鲜NK细胞表型分析,外周血单核细胞冻存用于NCR基因分型,血清用于NCR配体定量。
  • 从电子病历提取白细胞、中性粒细胞、单核细胞计数及乳酸脱氢酶水平。

主要发现

  • 单因素分析中,单核细胞增多、中性粒细胞增多、白细胞增多、高LDH、高sBAG6水平及NCR3转录本水平降低与总生存差相关。
  • NCR3转录本水平与年龄、转移部位数、单核细胞计数、LDH及sBAG6水平相关。
  • 中性粒细胞增多与高sBAG6水平相关。
  • 多因素分析中NCR3是唯一与总生存(P=0.003)和无进展生存(P=0.009)独立相关的固有免疫参数。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Innate immunity represents the first step of activation of the immune system and dictates the quality of adaptive immune responses. Studies have reported links between systemic inflammatory or innate immune markers and prognosis in patients with lung cancer. To our knowledge, the prospective and concomitant study of these systemic markers has never been performed. METHODS: Advanced treatment-naive non-small cell lung cancer (NSCLC) patients eligible for first-line platinum-based chemotherapy were prospectively included from December 2012 to July 2015 (N = 148). Blood samples of patients were collected before the first cycle for fresh NK cell phenotyping. Peripheral blood mononuclear cells were cryopreserved for natural cytotoxicity receptor (NCR) genotyping as well as sera for NCR's ligand quantification. Data on leukocytes, neutrophils and monocyte counts and lactate dehydrogenase (LDH) levels were extracted from electronic medical records. RESULTS: Among all studied markers, monocytosis, neutrophilia, leucocytosis, high LDH and sBAG6 levels and reduced levels of NCR3 transcripts were associated with poor overall survival (OS) in univariate analysis. The levels of NCR3 transcripts was linked to age, number of metastatic sites, monocyte counts, LDH and sBAG6 levels. Neutrophilia was associated to high sBAG6 levels. NCR3 was the unique innate immune parameter that remained as an independent factor associated with both OS (P = 0.003) and progression-free survival (P = 0.009) in the multivariate analysis. CONCLUSION: This study brought evidence that these biomarkers are entangled; parameters associated with an inflammatory process were related to reduced levels of NCR3 transcripts. Finally, the level of NCR3 transcripts was independently associated with outcomes in treatment-naive patients with advanced NSCLC.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Charrier M, Mezquita L, Lueza B, et al. Circulating innate immune markers and outcomes in treatment-naïve advanced non-small cell lung cancer patients. Eur J Cancer. 2019. PMID: 30648633. doi:10.1016/j.ejca.2018.12.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。